Onset of psoriasis following treatment with tocilizumab.
Laurent
S
S
Le Parc
J-M
JM
Clérici
T
T
Bréban
M
M
Mahé
E
E
D000287:Administration, Topical; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001168:Arthritis / Q000188:drug therapy; D005260:Female; D006801:Humans; D007155:Immunologic Factors / Q000009:adverse effects*; D008875:Middle Aged; D011565:Psoriasis / Q000139:chemically induced*; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007155:Immunologic Factors; C502936:tocilizumab